389 related articles for article (PubMed ID: 21441298)
1. Castleman's disease: from basic mechanisms to molecular therapeutics.
El-Osta HE; Kurzrock R
Oncologist; 2011; 16(4):497-511. PubMed ID: 21441298
[TBL] [Abstract][Full Text] [Related]
2. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
Uldrick TS; Polizzotto MN; Yarchoan R
Curr Opin Oncol; 2012 Sep; 24(5):495-505. PubMed ID: 22729151
[TBL] [Abstract][Full Text] [Related]
4. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman's disease induced with anti-CD20.
Cervera Grau JM; Galiana Esquerdo G; Llorca Ferrándiz C; Briceño García H; Díaz Castellano M; Férriz Moreno P
Clin Transl Oncol; 2006 Jul; 8(7):540-1. PubMed ID: 16870545
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of iatrogenic multicentric Castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient.
Speicher DJ; Sehu MM; Mollee P; Shen L; Johnson NW; Faoagali JL
Am J Transplant; 2014 May; 14(5):1207-13. PubMed ID: 24674650
[TBL] [Abstract][Full Text] [Related]
6. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels.
Newsom-Davis T; Bower M; Wildfire A; Thirlwell C; Nelson M; Gazzard B; Stebbing J
Leuk Lymphoma; 2004 Sep; 45(9):1939-41. PubMed ID: 15223659
[TBL] [Abstract][Full Text] [Related]
7. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
[TBL] [Abstract][Full Text] [Related]
8. Fifty years of multicentric Castleman's disease.
Waterston A; Bower M
Acta Oncol; 2004; 43(8):698-704. PubMed ID: 15764213
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
Nishi J; Maruyama I
Leuk Lymphoma; 2000 Jul; 38(3-4):387-94. PubMed ID: 10830746
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous castleman's disease responds to anti interleukin-6 treatment.
Ahmed B; Tschen JA; Cohen PR; Zaki MH; Rady PL; Tyring SK; Corringham RE; Kurzrock R
Mol Cancer Ther; 2007 Sep; 6(9):2386-90. PubMed ID: 17766835
[TBL] [Abstract][Full Text] [Related]
11. Castleman's disease--a two compartment model of HHV8 infection.
Schulte KM; Talat N
Nat Rev Clin Oncol; 2010 Sep; 7(9):533-43. PubMed ID: 20603649
[TBL] [Abstract][Full Text] [Related]
12. Multicentric Castleman's disease in a Ghanaian adult.
Dei-Adomakoh YA; Segbefia C; Ekem I; Taylor A
Ghana Med J; 2013 Jun; 47(2):92-5. PubMed ID: 23966747
[TBL] [Abstract][Full Text] [Related]
13. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
[TBL] [Abstract][Full Text] [Related]
14. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
[TBL] [Abstract][Full Text] [Related]
15. Multicentric Castleman's disease in India - Does EBV rather than HHV8 play a role?
Bhanvadia V; Shet T; Rao V; Epari S; Gujral S; Jain H; Bagal B; Sengar M
Indian J Pathol Microbiol; 2021; 64(2):302-309. PubMed ID: 33851624
[TBL] [Abstract][Full Text] [Related]
16. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.
Corbellino M; Bestetti G; Scalamogna C; Calattini S; Galazzi M; Meroni L; Manganaro D; Fasan M; Moroni M; Galli M; Parravicini C
Blood; 2001 Dec; 98(12):3473-5. PubMed ID: 11719390
[TBL] [Abstract][Full Text] [Related]
17. Treatment of multicentric Castleman’s disease in HIV-1 infected and uninfected patients: a systematic review.
Rokx C; Rijnders BJ; van Laar JA
Neth J Med; 2015 Jun; 73(5):202-10. PubMed ID: 26087799
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Castleman's disease.
Dispenzieri A; Gertz MA
Curr Treat Options Oncol; 2005 May; 6(3):255-66. PubMed ID: 15869736
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic multicentric Castleman's disease: a systematic literature review.
Liu AY; Nabel CS; Finkelman BS; Ruth JR; Kurzrock R; van Rhee F; Krymskaya VP; Kelleher D; Rubenstein AH; Fajgenbaum DC
Lancet Haematol; 2016 Apr; 3(4):e163-75. PubMed ID: 27063975
[TBL] [Abstract][Full Text] [Related]
20. Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid.
Lee JP; Kim DK; Oh DY; Paik JH; Moon KC; Kim S; Kim YS
Clin Nephrol; 2011 Feb; 75(2):165-70. PubMed ID: 21255547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
